Evidence map›Paper›PMID 42400498›Full record

ArticleThe Australian and New Zealand journal of psychiatry2026

Cardiometabolic screening, elevated results and clinical follow-up actions in Māori and non-Māori with psychosis in Canterbury, Aotearoa New Zealand.

Nathan Monk, Emily Barrett, Julie Fitzjohn, Mau Te Rangimarie Clark, Melissa Kerdemelidis, Ruth Cunningham, Andre McLachlan, Waikaremoana Waitoki, Richard Porter, Cameron Lacey

Abstract read
In one paragraph

Article in The Australian and New Zealand journal of psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Nathan MonkDepartment of Psychological Medicine, University of Otago, Christchurch, New Zealand.ORCID 0000-0002-8932-7434
Emily BarrettDepartment of Psychological Medicine, University of Otago, Christchurch, New Zealand.ORCID 0009-0002-3806-1821
Julie FitzjohnSpecialist Mental Health Service, Health New Zealand - Canterbury (Te Whatu Ora - Waitaha), Christchurch, New Zealand.
Mau Te Rangimarie ClarkDepartment of Psychological Medicine, University of Otago, Christchurch, New Zealand.ORCID 0000-0002-7133-8020
Melissa KerdemelidisPopulation Health Gain, Service Improvement and Innovation, Health New Zealand - Canterbury (Te Whatu Ora - Waitaha), Christchurch, New Zealand.
Ruth CunninghamDepartment of Public Health, University of Otago, Wellington, New Zealand.ORCID 0000-0003-0090-3579
Andre McLachlanCentre for Health and Social Practice, Waikato Institute of Technology, Hamilton, New Zealand.
Waikaremoana WaitokiFaculty of Māori and Indigenous Studies, The University of Waikato, Hamilton, New Zealand.ORCID 0000-0002-0174-0065
Richard PorterDepartment of Psychological Medicine, University of Otago, Christchurch, New Zealand.ORCID 0000-0002-8695-3966
Cameron LaceyElimbias Health, Christchurch, New Zealand.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveEstimate and compare rates of cardiometabolic blood screening, elevated results and clinical follow-up actions for Māori and non-Māori mental health service users with psychosis in Canterbury, Aotearoa New Zealand.

methodsA retrospective cohort study (

results887/3840 (23%) of Canterbury Specialist Mental Health Service users with psychosis were Māori. First-year screening rates were modest (31-44%), similar by ethnicity and broadly higher among clozapine/olanzapine users. Māori had higher odds of both elevated lipids and HbA1c. About one-third of elevated results were followed up with re-testing within 1 year. Rates of follow-up testing and medication dispensing were broadly similar for Māori and non-Māori, except Māori were more likely to receive repeat HbA1c testing after an elevated result (odds ratio = 1.71 [1.16, 2.50]).

conclusionsFindings highlight large gaps in cardiometabolic screening and follow-up actions among Māori and non-Māori Specialist Mental Health Service users with psychosis. Māori presented with psychosis 4 years younger, had significantly higher rates of elevated cardiometabolic risk markers and were more likely to receive HbA1c re-testing following an elevated result.

Indexed as

Cardiovascular DiseasesMass ScreeningPsychotic DisordersAdolescentAdultFemaleFollow-Up StudiesGlycated HemoglobinHumansMaleMaori PeopleMiddle AgedNew ZealandRetrospective StudiesYoung AdultGlycated Hemoglobinantipsychotic medicationcardiometabolic riskHbA1chealth inequitylipidsMāori healthPsychosis

Identifiers

PMID42400498
PMCPMC13620362

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.